CAU
DNA icon

Caxton Associates (UK)’s Ginkgo Bioworks DNA Stock Holding History

Caxton Associates (UK)’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
154,647
+85,869
+125% +$718K 0.03% 319
2026
Q1 		$422K Sell
68,778
-103,802
-60% -$863K 0.01% 534
2025
Q4 		$1.43M Buy
172,580
+42,992
+33% +$463K 0.03% 273
2025
Q3 		$1.89M Buy
+129,588
New +$1.55M 0.04% 213

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Caxton Associates (UK)'s DNA Position: Q2 2026 in Review

Caxton Associates (UK) increased its Ginkgo Bioworks (DNA) stake by 125% in Q2 2026, buying an estimated $718K and bringing the position to 154,647 shares worth $1.53M. The position accounts for 0.03% of the portfolio, ranked #319.

Caxton Associates (UK) first reported a position in DNA in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.89M in Q3 2025. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Caxton Associates (UK) held 154,647 shares of Ginkgo Bioworks worth $1.53M as of Q2 2026.
  • Caxton Associates (UK) bought 85,869 Ginkgo Bioworks shares in Q2 2026, an estimated $718K.
  • Ginkgo Bioworks made up 0.03% of Caxton Associates (UK)'s portfolio in Q2 2026, its #319 holding.
  • Caxton Associates (UK) first reported a position in Ginkgo Bioworks in Q3 2025 and has held it in 4 quarters since.
  • Caxton Associates (UK)'s Ginkgo Bioworks position peaked at $1.89M in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.